Figure 2 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model

Le résumé fourni par la source

Combination treatment of EVs and anti–PD-1/anti–PD-L1 improves antitumor immunity on day 20 after tumor inoculation. A, Mice with OVA-expressing B16 melanoma were treated with PBS or EVs intravenously and anti–PD-1/PD-L1 intraperitoneally as indicated. Mice were sacrificed on day 20 for further analysis. B, Tumor volume was measured on day 20. C, The total number of OVA-specific CD8+ T cells in the spleen was determined using flow cytometry. D, ELISPOT assay was performed to detect IFNγ-secreting cells after in vitro restimulation with the CD4 peptide OVA323–339, CD8 peptide SIINFEKL, whole OVA protein, or B16 melanoma cells. The data represent one experiment. Dots represent a single mouse, 4 to 5 mice per group, and data are presented as the mean ± SEM, except for figure 2C which is displayed as the mean ± SD. Data were analyzed using the Kruskal–Wallis test with Dunn test for multiple comparisons. *, P < 0.05; **, P < 0.01; and ***, P < 0.001.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.